Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026-24 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml)
Description
The TK aims to conclude discount contracts pursuant to Section 130a(8) SGB V with all suitable pharmaceutical companies for the active substance Aflibercept (ATC: S01LA05; strength: 40 mg/ml). The contract will be concluded within the framework of the TK's Open-House procedure: Individual negotiations on contract terms will not be conducted; uniform conditions apply. The TK does not guarantee exclusivity to individual contracting partners. The contract term is a maximum of 12 months, commencing on 01.08.2026. The contract ends at the latest on 31.07.2027, regardless of the date of contract conclusion. The contract can be extended by 12 months. All further information can be found in the participation and contract documents.
CPV codes
Documents & submission
Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.
Related tenders
Germany – Miscellaneous medical devices and products – VE 473.05 105 Deckenversorgungseinheiten Medien
Universitätsklinikum HeidelbergGermanyMiscellaneous medical devices and productsInstallation services of medical equipmentDeadline in 29 daysPublished on Nov 19, 2026
Germany – Pharmaceutical products – Arzneimittelverträge mit Beitrittsoption
BARMER Beschaffung und VergabeGermanyPharmaceutical productsDeadline in 620 daysPublished on Nov 19, 2026
Germany – Medical equipments, pharmaceuticals and personal care products – Absaugung, Invasive Blutdruckmessung und Regionalanästhesie
EK-UNICO GmbHGermanyMedical equipments, pharmaceuticals and personal care productsVenepuncture, blood sampling devicesAnaesthesia and resuscitationDeadline in 32 daysPublished on Nov 19, 2026
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit dem Wirkstoff Aflibercept, ausgenommen 114,3 mg/ml (ATC-Code: S01LA05).
AOK Niedersachsen. Die Gesundheitskasse.GermanyPharmaceutical productsDeadline in 707 daysPublished on Nov 19, 2026